Cargando…
Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from folium nelumbinis and has been demonstrated to have beneficial effects on a high-fat diet (HFD) i...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295953/ https://www.ncbi.nlm.nih.gov/pubmed/32581811 http://dx.doi.org/10.3389/fphar.2020.00858 |
_version_ | 1783546744696471552 |
---|---|
author | Cui, Huantian Li, Yuting Cao, Min Liao, Jiabao Liu, Xiangguo Miao, Jing Fu, Hui Song, Ruiwen Wen, Weibo Zhang, Zhaiyi Wang, Hongwu |
author_facet | Cui, Huantian Li, Yuting Cao, Min Liao, Jiabao Liu, Xiangguo Miao, Jing Fu, Hui Song, Ruiwen Wen, Weibo Zhang, Zhaiyi Wang, Hongwu |
author_sort | Cui, Huantian |
collection | PubMed |
description | Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from folium nelumbinis and has been demonstrated to have beneficial effects on a high-fat diet (HFD) induced hepatic steatosis model. However, the effect of the altered metabolites of nuciferine on NAFLD has not yet been elucidated. In this study, we established a NAFLD rat model using HFD and treated with nuciferine. The lipid content levels, pro-inflammatory cytokines, and oxidative stress were investigated to access the therapeutic effects of nuciferine. Additionally, the metabolic regulatory mechanisms of nuciferine on NAFLD were analyzed using untargeted metabolomics. Gene expression of the key enzymes related to the changed metabolic pathways following nuciferine intervention was also investigated. The results showed that nuciferine treatment significantly reduced the body weight, levels of lipids, and liver enzymes in the blood and improved the hepatic steatosis in the NAFLD rat model. Nuciferine treatment also increased the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and decreased the levels of methane dicarboxylic aldehyde (MDA) in the liver. Nuciferine treatment decreased the serum levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) and upregulated the gene expression of IL-6, IL-1β, and TNF-α in the liver. Metabolomic analysis indicated a metabolism disorder in the NAFLD rat model reflected in a dysfunction of the glycerophospholipid, linoleic acid, alpha-linolenic acid, arginine and proline metabolism. Conversely, treatment with nuciferine improved the metabolic disorder in the NAFLD rat model. Nuciferine treatment also regulated the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver. In conclusion, our study demonstrated an amelioration of the metabolic disorders following nuciferine treatment in NAFLD rat model. Our study contributes to the understanding of the effects and mechanisms of drugs for complex diseases using metabolomic analysis and experimental approaches. |
format | Online Article Text |
id | pubmed-7295953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72959532020-06-23 Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease Cui, Huantian Li, Yuting Cao, Min Liao, Jiabao Liu, Xiangguo Miao, Jing Fu, Hui Song, Ruiwen Wen, Weibo Zhang, Zhaiyi Wang, Hongwu Front Pharmacol Pharmacology Metabolomic analysis has been used to characterize the effects and mechanisms of drugs for nonalcoholic fatty liver disease (NAFLD) at the metabolic level. Nuciferine is an active component derived from folium nelumbinis and has been demonstrated to have beneficial effects on a high-fat diet (HFD) induced hepatic steatosis model. However, the effect of the altered metabolites of nuciferine on NAFLD has not yet been elucidated. In this study, we established a NAFLD rat model using HFD and treated with nuciferine. The lipid content levels, pro-inflammatory cytokines, and oxidative stress were investigated to access the therapeutic effects of nuciferine. Additionally, the metabolic regulatory mechanisms of nuciferine on NAFLD were analyzed using untargeted metabolomics. Gene expression of the key enzymes related to the changed metabolic pathways following nuciferine intervention was also investigated. The results showed that nuciferine treatment significantly reduced the body weight, levels of lipids, and liver enzymes in the blood and improved the hepatic steatosis in the NAFLD rat model. Nuciferine treatment also increased the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and decreased the levels of methane dicarboxylic aldehyde (MDA) in the liver. Nuciferine treatment decreased the serum levels of interleukin (IL)-6, IL-1β, and tumor necrosis factor-alpha (TNF-α) and upregulated the gene expression of IL-6, IL-1β, and TNF-α in the liver. Metabolomic analysis indicated a metabolism disorder in the NAFLD rat model reflected in a dysfunction of the glycerophospholipid, linoleic acid, alpha-linolenic acid, arginine and proline metabolism. Conversely, treatment with nuciferine improved the metabolic disorder in the NAFLD rat model. Nuciferine treatment also regulated the gene expression of key enzymes related to the glycerophospholipid, linoleic acid, and alpha-linolenic acid metabolism pathways in the liver. In conclusion, our study demonstrated an amelioration of the metabolic disorders following nuciferine treatment in NAFLD rat model. Our study contributes to the understanding of the effects and mechanisms of drugs for complex diseases using metabolomic analysis and experimental approaches. Frontiers Media S.A. 2020-06-09 /pmc/articles/PMC7295953/ /pubmed/32581811 http://dx.doi.org/10.3389/fphar.2020.00858 Text en Copyright © 2020 Cui, Li, Cao, Liao, Liu, Miao, Fu, Song, Wen, Zhang and Wang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cui, Huantian Li, Yuting Cao, Min Liao, Jiabao Liu, Xiangguo Miao, Jing Fu, Hui Song, Ruiwen Wen, Weibo Zhang, Zhaiyi Wang, Hongwu Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease |
title | Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease |
title_full | Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease |
title_fullStr | Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease |
title_full_unstemmed | Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease |
title_short | Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease |
title_sort | untargeted metabolomic analysis of the effects and mechanism of nuciferine treatment on rats with nonalcoholic fatty liver disease |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295953/ https://www.ncbi.nlm.nih.gov/pubmed/32581811 http://dx.doi.org/10.3389/fphar.2020.00858 |
work_keys_str_mv | AT cuihuantian untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT liyuting untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT caomin untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT liaojiabao untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT liuxiangguo untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT miaojing untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT fuhui untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT songruiwen untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT wenweibo untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT zhangzhaiyi untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease AT wanghongwu untargetedmetabolomicanalysisoftheeffectsandmechanismofnuciferinetreatmentonratswithnonalcoholicfattyliverdisease |